164 related articles for article (PubMed ID: 9427259)
1. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
Maier-Lenz H; Hauns B; Haering B; Koetting J; Mross K; Unger C; Bauknecht T; du Bois A; Meerpohl HG; Hollaender N; Diergarten K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-16-S19-19. PubMed ID: 9427259
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
3. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
5. Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors.
Creaven PJ; Raghavan D; Perez RP; Pendyala L; Berghorn EJ; Loewen G; Meropol NJ
Semin Oncol; 1996 Dec; 23(6 Suppl 16):26-31. PubMed ID: 9007117
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Casadei Giunchi D; Gentile A; Salzano E
Semin Oncol; 1996 Feb; 23(1 Suppl 1):19-23. PubMed ID: 8629031
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
Chang AY; Boros L; Asbury R; Hui L; Rubins J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-69-S17-71. PubMed ID: 9374098
[TBL] [Abstract][Full Text] [Related]
8. Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule.
Garcia AA; Parimoo D; Dimery I; Rogers M; Jeffers S; Muggia FM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-62-S19-66. PubMed ID: 9427269
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with upper gastrointestinal carcinomas.
Ajani JA
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer.
Marangolo M; Emiliani E; Rosti G; Giannini M; Vertogen B; Zumaglini F
Semin Oncol; 1996 Dec; 23(6 Suppl 16):124-7. PubMed ID: 9007139
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and carboplatin in head and neck cancer.
Dunphy F; Boyd J; Dunleavy T
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-25-S19-27. PubMed ID: 9427261
[TBL] [Abstract][Full Text] [Related]
13. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seidman AD; Hudis CA; McCaffrey J; Tong W; Currie V; Moynahan ME; Theodoulou M; Tepler I; Gollub M; Norton L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-72-S17-76. PubMed ID: 9374099
[TBL] [Abstract][Full Text] [Related]
14. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 8):3-8. PubMed ID: 7939760
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Benasso M; Numico G; Rosso R; Merlano M; Ricci I; Gentile A
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-46-S19-50. PubMed ID: 9427266
[TBL] [Abstract][Full Text] [Related]
19. Single-agent paclitaxel as a 3-hour infusion.
Gatzemeier U; Neuhauss R; Schluter I; von Pawel J; Wagner H; Diergarten K
Semin Oncol; 1996 Dec; 23(6 Suppl 16):94-7. PubMed ID: 9007132
[TBL] [Abstract][Full Text] [Related]
20. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
